Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors

[11] Nishiwaki Y(2004)Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting Clin Cancer Res 10 6487-6501

[12] Ohe Y(2005)Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations J Natl Cancer Inst 97 1185-1194

[13] Yang JJ(2005)Establishment of a human non-small cell lung cancer cell line resistant to gefitinib Int J Cancer 116 36-44

[14] Chewaskulyong B(2005)TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 5892-5899

[15] Jiang H(2004)Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1 J Clin Oncol 22 777-784

[16] Duffield EL(2004)Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2 J Clin Oncol 22 785-794

[17] Watkins CL(2007)Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 1545-1552

[18] Armour AA(2007)Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells Clin Cancer Res 13 3413-3422

[19] Fukuoka M(2006)Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors Mol Cancer Ther 5 2676-2684

[20] Tortora G(2007)Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer Clin Cancer Res 13 s4628-s4631

[11] Nishiwaki Y(2004)Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting Clin Cancer Res 10 6487-6501

[12] Ohe Y(2005)Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations J Natl Cancer Inst 97 1185-1194

[13] Yang JJ(2005)Establishment of a human non-small cell lung cancer cell line resistant to gefitinib Int J Cancer 116 36-44

[14] Chewaskulyong B(2005)TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 5892-5899

[15] Jiang H(2004)Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1 J Clin Oncol 22 777-784

[16] Duffield EL(2004)Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2 J Clin Oncol 22 785-794

[17] Watkins CL(2007)Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 1545-1552

[18] Armour AA(2007)Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells Clin Cancer Res 13 3413-3422

[19] Fukuoka M(2006)Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors Mol Cancer Ther 5 2676-2684

[20] Tortora G(2007)Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer Clin Cancer Res 13 s4628-s4631